This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' Recap: Markets Behaving Badly

Finally, there was also positive news from another troubled region of the globe, Europe, where Bunch noted that PPG saw an encouraging fourth quarter with no volume declines. He said the European auto business is starting to show signs of life, which is very encouraging.

With all of those positives, Bunch said PPG has plenty of cash on hand for acquisitions or returns of capital to shareholders in 2014. Cramer said that even with some weakness in China, PPG has a lot to like elsewhere in the world.

Sell Block

A big part of investing is knowing who to trust, Cramer told viewers in his Thursday "Sell Block" segment. That's why when colleague Herb Greenberg raised the red flag on Valeant Pharmaceuticals (VRX - Get Report), Cramer took notice.

Shares of Valeant are up 112% over the past 12 months, and this beloved stock currently has 16 buy ratings, two holds and just one sell -- making Greenberg's bearish case the minority view.

But according to Greenberg, we've seen the Valeant story many times before and it always ends very badly for shareholders. At issue: Valeant's voracious appetite for growth via acquisition. The company has done no fewer than 60 acquisitions in the past six years but, as Greenberg noted, the company will need many, many more to achieve its self-stated goal of becoming a top-five pharma player by 2016.

Growing by acquisition is not inherently a bad thing. What was worrisome to Greenberg was the fact that Valeant's organic growth actually fell by 9% last quarter, with guidance coming in at the low end of expectations. With organic growth faltering, Valeant will have no choice but to start issuing more stock to pay for its continued growth, thereby diluting existing shareholders. Otherwise, the company risks having its growth stall, a scenario which would also be determential to shareholders.

Cramer said the term for companies that grow only via acquisition is a "roll-up" company, and while there are some success stories, they all hinge on making successful acquisitions that continue to grow organically afterwards. That's why Cramer said if Greenberg is worried, he is, too.

Lightning Round

In the Lightning Round, Cramer was bullish on Groupon (GRPN), Yelp (YELP), F5 Networks (FFIV), Visa (V) and SolarCity (SCTY).

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
EBAY $59.20 0.53%
PPG $223.31 -1.14%
VRX $210.42 0.49%
AAPL $130.28 0.47%
FB $81.53 -1.07%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs